Credit Suisse has released a biotech research report that has their top picks for upside potential in the biotech segment for 2015.
Chris Lange Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep…
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Tuesday, September 2, 2014.
ThinkstockIn what was yet another very volatile week for the markets, insider selling and insider buying has been active. We have evaluated some of the top insider selling transactions this last week.…
These are the top analyst upgrades, downgrades and initiations from Wall Street firms on Monday, July 21, 2014. They include Apple, ARM Holdings, DaVita Healthcare, General Electric, GoPro and Itron.
ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street has loudly stepped up to the plate and advised investors to buy…
Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would like to see several competing biotechs join in on the fun.
A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally from the hard sell-off. Here are the top large cap biotech stocks…
A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as a "return to normalcy" following the roller coaster ride of early 2014.
These are the top analyst upgrades, downgrades and initiations from Wall Street on Wednesday, April 16, 2014. They include Control4, Cree, NetApp, Twitter, Yahoo! and Yelp.
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at…
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage…
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, March 17, 2014. The include Baker Hughes, Cameron, Cisco Systems, Facebook and VeriSign.
